Sysmex Europe
Menu

The value of the immature platelet count for managing immune thrombocytopenia (ITP) treatment and assessing the risk of bleeding

The treatment of immune thrombocytopenia (ITP) can be challenging. The immature platelet count (IPF) can be used in ITP as a supportive information to assess whether the treatment mechanism is having an effect: To have a supportive parameter to answer the clinical question as to whether the observed increase in the platelet count is due to increased platelet production or inhibition of antibody-mediated platelet destruction. Due to the higher reactivity and haemostatic potential of immature platelets, an increased immature platelet count was also found to be associated with a lower risk of bleeding with severely thrombocytopenic patients.
File type:
pdf
File size:
573 KB
Release:
18-12-23

 

 


Copyright © Sysmex Europe SE. All rights reserved.